Contact
searchSearch
HMP Global

Hidradenitis Suppurativa

Featured

News
Emerging JAK1 and C5a Inhibitors Show Promise in Hidradenitis Suppurativa Network Meta-Analysis
03/31/2026
Riya Gandhi, MA
Comparative data highlight improved efficacy and tolerability signals with investigational therapies vs current standards.
Comparative data highlight improved efficacy and tolerability signals with investigational therapies vs current standards.
Comparative data highlight...
03/31/2026
The Dermatologist
HS
News
Povorcitinib Demonstrates Meaningful Clinical Response in Anti-TNF–Experienced Hidradenitis Suppurativa Patients at 24 Weeks
03/31/2026
Riya Gandhi, MA
Phase 3 interim data show improved HiSCR responses and rapid pain reduction in a difficult-to-treat population.
Phase 3 interim data show improved HiSCR responses and rapid pain reduction in a difficult-to-treat population.
Phase 3 interim data show...
03/31/2026
The Dermatologist
Gottlieb
Clinical Insights
Reimagining Hidradenitis Suppurativa Care: Early Recognition, Therapeutic Innovation, and Multidisciplinary Care Across the Patient Journey
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical and surgical management.
During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical and surgical management.
During an expert discussion,...
03/02/2026
The Dermatologist
Yoo
Clinical Insights
Ultrasound as a Transformative Tool in Dermatology: From Cosmetic Imaging to Hidradenitis Suppurativa Assessment and Emerging Therapies
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dr Yoo and Dr Gottlieb reviewed the principles and applications of handheld ultrasound devices, sonographic assessment of hidradenitis suppurativa, aesthetic procedure guidance, and the expanding landscape of HS therapeutics.
Dr Yoo and Dr Gottlieb reviewed the principles and applications of handheld ultrasound devices, sonographic assessment of hidradenitis suppurativa, aesthetic procedure guidance, and the expanding landscape of HS therapeutics.
Dr Yoo and Dr Gottlieb reviewed...
03/02/2026
The Dermatologist
Face
FDA Alerts
Bimekizumab FDA Approved for Moderate to Severe Hidradenitis Suppurativa
11/20/2024
Riya Gandhi, MA
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug...
11/20/2024
The Dermatologist
Hidradenitis Suppurativa
News
Evolving Treatment Paradigms for Hidradenitis Suppurativa: The Role of Biologics
10/31/2024
Jessica Garlewicz
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS...
10/31/2024
The Dermatologist
FDA Alerts
Secukinumab Approved as New Biologic Treatment Option for Hidradenitis Suppurativa
11/01/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug...
11/01/2023
The Dermatologist
News
Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa
07/18/2023
Jessica Garlewicz
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a...
07/18/2023
The Dermatologist
News
Smoking and Obesity Are Important Research Questions for Managing Hidradenitis Suppurativa
04/10/2023
Lisa Kuhns, PhD, MD
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority...
04/10/2023
The Dermatologist
News
Complete Remission of Hidradenitis Suppurativa Reported After Treatment With Thoracodorsal Artery Perforator Flap
04/05/2023
Lisa Kuhns, PhD, MD
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator...
04/05/2023
The Dermatologist
News
Effectiveness and Pain Reduction Identified as the Most Important Treatment Attributes in Hidradenitis Suppurativa Management
01/31/2023
Lisa Kuhns, PhD, MD
In a multinational discrete choice experiment, researchers aimed to determine which treatment attributes adult patients with HS in Europe consider the most important in treatment decision-making.
In a multinational discrete choice experiment, researchers aimed to determine which treatment attributes adult patients with HS in Europe consider the most important in treatment decision-making.
In a multinational discrete...
01/31/2023
The Dermatologist

Q&As

Q&As
Dr Amit Garg: Comorbidity Screening in HS
05/19/2021
Amit Garg, MD, shares insights into Hidradenitis Suppurativa and discusses his latest study, “Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations”.
Amit Garg, MD, shares insights into Hidradenitis Suppurativa and discusses his latest study, “Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations”.
Amit Garg, MD, shares insights...
05/19/2021
The Dermatologist
Q&As
Dr Haley Naik on Hidradenitis Suppurativa: Current Medical and Surgical Management
04/24/2021
Dr Haley Naik, MD, MHSc, FAAD joined The Dermatologist prior to her session at AAD VMX 2021 to discuss the current medical and surgical management options for hidradenitis suppurativa.
Dr Haley Naik, MD, MHSc, FAAD joined The Dermatologist prior to her session at AAD VMX 2021 to discuss the current medical and surgical management options for hidradenitis suppurativa.
Dr Haley Naik, MD, MHSc, FAAD...
04/24/2021
The Dermatologist
Q&As
The Who and When of Intralesional Injections for HS Treatment
03/26/2021
Steven R. Cohen, MD, MPH, met with The Dermatologist to discuss the efficacy of high dose intralesional triamcinolone (ILTAC) for hidradenitis suppurativa.
Steven R. Cohen, MD, MPH, met with The Dermatologist to discuss the efficacy of high dose intralesional triamcinolone (ILTAC) for hidradenitis suppurativa.
Steven R. Cohen, MD, MPH, met...
03/26/2021
The Dermatologist
Joseph F. Merola, MD, MMSc
Q&As
A New Era in Dermatomyositis: A Conversation at the Rheumatology-Dermatology Interface
09/16/2026
Joseph F. Merola, MD, MMSc; Katharina S. Shaw, MD, FAAD
Masterclasses in Dermatology Co-Chair Dr Joseph Merola chats with Dr Katharina Shaw, SVP, Dermatology Franchise, Priovant Therapeutics, about the recent FDA approval of Lisraya as the first oral therapy for adult dermatomyositis.
Masterclasses in Dermatology Co-Chair Dr Joseph Merola chats with Dr Katharina Shaw, SVP, Dermatology Franchise, Priovant Therapeutics, about the recent FDA approval of Lisraya as the first oral therapy for adult dermatomyositis.
Masterclasses in Dermatology...
09/16/2026
The Dermatologist
sunscreen
Q&As
FDA Approves Bemotrizinol: What Dermatologists Need to Know
06/11/2026
Jane Y. Yoo, MD; Riya Gandhi, MA
The Dermatologist spoke with Dr Jane Yoo about the FDA’s landmark approval of bemotrizinol.
The Dermatologist spoke with Dr Jane Yoo about the FDA’s landmark approval of bemotrizinol.
The Dermatologist spoke with Dr...
06/11/2026
The Dermatologist
Omar Ibrahimi, MD, PhD
Q&As
Laser Focused: The Latest Trends in Laser and Light Devices
05/15/2026
Omar A. Ibrahimi, MD, PhD; Riya Gandhi, MA
In this Expert Q&A, Dr Ibrahimi highlights the technologic advancements that are reshaping clinical practice.
In this Expert Q&A, Dr Ibrahimi highlights the technologic advancements that are reshaping clinical practice.
In this Expert Q&A, Dr Ibrahimi...
05/15/2026
The Dermatologist
Omar Ibrahimi, MD, PhD
Q&As
Devices I Can’t Live Without and What I’m Excited About in 2026
05/14/2026
Omar A. Ibrahimi, MD, PhD; Riya Gandhi, MA
In this expert Q&A, Dr Ibrahimi offers insight into energy-based technologies from trusted lasers for resurfacing and vascular conditions to emerging advancements like focal point technology.
In this expert Q&A, Dr Ibrahimi offers insight into energy-based technologies from trusted lasers for resurfacing and vascular conditions to emerging advancements like focal point technology.
In this expert Q&A, Dr Ibrahimi...
05/14/2026
The Dermatologist
Omar Ibrahimi
Q&As
Scar Revision Strategies: When to Intervene and the Role of Laser Therapy
04/27/2026
Omar A. Ibrahimi, MD, PhD; Riya Gandhi, MA
This expert Q&A explores when scar revision is warranted, from functional impairment to patient-driven concerns.
This expert Q&A explores when scar revision is warranted, from functional impairment to patient-driven concerns.
This expert Q&A explores when...
04/27/2026
The Dermatologist
Jane Yoo
Q&As
Sunscreen Filters: What’s New in UVA Protection, Formulations, and Global Options
03/17/2026
Jane Y. Yoo, MD
Explore the latest advances in sunscreen filter technology, including improved UVA coverage, photostability, and cosmetic formulations that enhance patient adherence.
Explore the latest advances in sunscreen filter technology, including improved UVA coverage, photostability, and cosmetic formulations that enhance patient adherence.
Explore the latest advances in...
03/17/2026
The Dermatologist
Part 3
Q&As
Rebuilding Confidence in Alopecia Areata: Multidisciplinary, Holistic Support for Patients and Families
11/03/2025
Brittany Craiglow, MD; Brett A. King, MD, PhD; Maryanne Makredes Senna, MD
Experts explore holistic and emotional support strategies to empower patients with alopecia areata—beyond medicine, toward identity and healing.
Experts explore holistic and emotional support strategies to empower patients with alopecia areata—beyond medicine, toward identity and healing.
Experts explore holistic and...
11/03/2025
The Dermatologist
part 2
Q&As
Part 2: Advancing the Treatment Landscape in Severe Alopecia Areata
09/01/2025
Brittany Craiglow, MD; Brett A. King, MD, PhD; Maryanne Makredes Senna, MD
In Part 2 of this expert interview series, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna explore the latest treatment strategies for severe alopecia areata.
In Part 2 of this expert interview series, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna explore the latest treatment strategies for severe alopecia areata.
In Part 2 of this expert...
09/01/2025
The Dermatologist
Part 1 roundtable
Q&As
Part 1: Understanding the Emotional and Physical Toll of Alopecia Areata
08/04/2025
Brittany Craiglow, MD; Brett A. King, MD, PhD; Maryanne Makredes Senna, MD
In this candid and powerful conversation, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna share their clinical experiences treating patients with severe alopecia areata.
In this candid and powerful conversation, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna share their clinical experiences treating patients with severe alopecia areata.
In this candid and powerful...
08/04/2025
The Dermatologist
Brandon Adler, MD
Q&As
Insights Into Photoprotection Updates
02/08/2024
Jessica Garlewicz
Dr Brandon Adler shared the latest updates in sunscreen usage, and how physicians can implement these changes in their practices.
Dr Brandon Adler shared the latest updates in sunscreen usage, and how physicians can implement these changes in their practices.
Dr Brandon Adler shared the...
02/08/2024
The Dermatologist

Multimedia

Dr Sherry Yang
Videos
Inflammation's Role in the Disease Progression of HS
11/17/2021
Sherry Yang, MD, FAAD
Dr Sherry Yang discusses the various causes of inflammation and their role in the disease progression of patients with HS.
Dr Sherry Yang discusses the various causes of inflammation and their role in the disease progression of patients with HS.
Dr Sherry Yang discusses the...
11/17/2021
The Dermatologist
Dr Sherry Yang
Videos
Demographics & Characteristics Associated With HS Diagnoses
11/12/2021
Sherry Yang, MD, FAAD
Dr Sherry Yang discusses patient demographics and characteristics that are associated with HS diagnoses.
Dr Sherry Yang discusses patient demographics and characteristics that are associated with HS diagnoses.
Dr Sherry Yang discusses patient...
11/12/2021
The Dermatologist
Dr Sherry Yang
Videos
How to Approach HS Treatment
11/05/2021
Sherry Yang, MD, FAAD
Dr Sherry Yang discusses how individualizing treatment plans for each patient is one of the best approaches to combatting HS symptoms.
Dr Sherry Yang discusses how individualizing treatment plans for each patient is one of the best approaches to combatting HS symptoms.
Dr Sherry Yang discusses how...
11/05/2021
The Dermatologist
Videos
Clinical Implications of HS and Hepatitis B/C
06/10/2021
Dr Cohen shares the clinical implications of hepatitis B and hepatitis C in patients with HS in this 8-minute video.
Dr Cohen shares the clinical implications of hepatitis B and hepatitis C in patients with HS in this 8-minute video.
Dr Cohen shares the clinical...
06/10/2021
The Dermatologist
Videos
Genetic Components and Hepatitis Risks in HS
06/10/2021
In this video interview, Dr Cohen highlights results of his recent study into HS and hepatitis B and C.
In this video interview, Dr Cohen highlights results of his recent study into HS and hepatitis B and C.
In this video interview, Dr...
06/10/2021
The Dermatologist
Podcasts
Updates in HS: Dr Rosenblum on Pathophysiology
12/15/2020
In this podcast, Michael Rosenblum, MD, reviews the pathophysiology of hidradenitis suppurativa and a possible immune activation signature that could potentially identify patients who may respond to TNF therapies.
In this podcast, Michael Rosenblum, MD, reviews the pathophysiology of hidradenitis suppurativa and a possible immune activation signature that could potentially identify patients who may respond to TNF therapies.
In this podcast, Michael...
12/15/2020
The Dermatologist
Podcasts
Dr Iltefat Hamzavi on Managing Hidradenitis Suppurativa
09/16/2020
In this podcast, Iltefat Hamzavi, MD, discusses therapeutic options for managing flares, the role of lasers, and new therapies in the pipeline for hidradenitis suppurativa.
In this podcast, Iltefat Hamzavi, MD, discusses therapeutic options for managing flares, the role of lasers, and new therapies in the pipeline for hidradenitis suppurativa.
In this podcast, Iltefat...
09/16/2020
The Dermatologist
Raj Chovatiya
Videos
Chronic Spontaneous Urticaria: Type 2 Inflammation and Mast Cell Hyperreactivity
09/01/2026
Raj Chovatiya, MD, PhD; Riya Gandhi, MA
Dr Raj Chovatiya explains how type 2 inflammation drives mast cell activation in chronic spontaneous urticaria (CSU), highlighting the roles of IL-4, IL-13, and IgE in both immune and neuroimmune pathways.
Dr Raj Chovatiya explains how type 2 inflammation drives mast cell activation in chronic spontaneous urticaria (CSU), highlighting the roles of IL-4, IL-13, and IgE in both immune and neuroimmune pathways.
Dr Raj Chovatiya explains how...
09/01/2026
The Dermatologist
Saturday Morning Live
Podcasts
Hyperpigmentation Prevention and Treatment: Melasma, PIH, and Oral Tranexamic Acid
08/13/2026
Joseph F. Merola, MD, MMSc; Alice Bendix Gottlieb, MD, PhD
Dr Andrew Alexis (Weill Cornell Medicine) joins hosts Dr Alice Gottlieb and Dr Joseph Merola to break down a practical, stage-by-stage approach to hyperpigmentation in skin of color.
Dr Andrew Alexis (Weill Cornell Medicine) joins hosts Dr Alice Gottlieb and Dr Joseph Merola to break down a practical, stage-by-stage approach to hyperpigmentation in skin of color.
Dr Andrew Alexis (Weill Cornell...
08/13/2026
The Dermatologist
Asempa
Videos
Myth Buster: Shared Decision-Making is Easy in Alopecia Areata
08/06/2026
Oyetewa Boluwatito Asempa, MD, FAAD; Riya Gandhi, MA
Shared decision-making in alopecia areata is often more complex than it appears. Dr Oyetewa Asempa discusses aligning treatment goals, managing expectations, and improving patient-clinician communication.
Shared decision-making in alopecia areata is often more complex than it appears. Dr Oyetewa Asempa discusses aligning treatment goals, managing expectations, and improving patient-clinician communication.
Shared decision-making in...
08/06/2026
The Dermatologist
Draelos
Videos
Myth Buster: Hair Regrowth is the Only Outcome That Matters
08/06/2026
Zoe Diana Draelos, MD; Riya Gandhi, MA
Hair regrowth is only one measure of success in alopecia areata. Dr Zoe Draelos highlights patient-centered outcomes, quality of life, emotional well-being, and long-term disease control.
Hair regrowth is only one measure of success in alopecia areata. Dr Zoe Draelos highlights patient-centered outcomes, quality of life, emotional well-being, and long-term disease control.
Hair regrowth is only one...
08/06/2026
The Dermatologist
Draelos
Videos
Myth Buster: Children are More Resilient to Alopecia Areata Than Adults
08/06/2026
Zoe Diana Draelos, MD; Riya Gandhi, MA
Pediatric alopecia areata can have profound emotional and social consequences. Dr Zoe Draelos examines the unique psychological challenges facing children and adolescents with the disease.
Pediatric alopecia areata can have profound emotional and social consequences. Dr Zoe Draelos examines the unique psychological challenges facing children and adolescents with the disease.
Pediatric alopecia areata can...
08/06/2026
The Dermatologist
Draelos
Videos
Myth Buster: Patients Will Adjust to Alopecia Areata Over Time
08/06/2026
Zoe Diana Draelos, MD; Riya Gandhi, MA
Adapting to alopecia areata isn't always a linear process. Dr Zoe Draelos discusses the lasting emotional impact of the disease and why ongoing psychosocial support remains essential.
Adapting to alopecia areata isn't always a linear process. Dr Zoe Draelos discusses the lasting emotional impact of the disease and why ongoing psychosocial support remains essential.
Adapting to alopecia areata...
08/06/2026
The Dermatologist
Asempa
Videos
Myth Buster: Dermatologists are Already Addressing the Psychosocial Burden of Alopecia Areata
08/06/2026
Oyetewa Boluwatito Asempa, MD, FAAD; Riya Gandhi, MA
Treating alopecia areata extends beyond managing hair loss. Dr Oyetewa Asempa explores gaps in psychosocial care, patient communication, and integrating mental health into clinical practice.
Treating alopecia areata extends beyond managing hair loss. Dr Oyetewa Asempa explores gaps in psychosocial care, patient communication, and integrating mental health into clinical practice.
Treating alopecia areata extends...
08/06/2026
The Dermatologist
Guttman
Videos
Myth Buster: If Treatment is Working, Patients can Stop it Immediately
08/06/2026
Emma Guttman-Yassky, MD, PhD; Riya Gandhi, MA
Successful alopecia areata treatment doesn't always mean therapy should end. Dr Emma Guttman discusses relapse risk, maintenance strategies, and setting realistic expectations for long-term disease management.
Successful alopecia areata treatment doesn't always mean therapy should end. Dr Emma Guttman discusses relapse risk, maintenance strategies, and setting realistic expectations for long-term disease management.
Successful alopecia areata...
08/06/2026
The Dermatologist
Emma Guttman
Videos
Myth Buster: Once a Patient Loses all Their Hair, Treatment Won’t Work
08/06/2026
Emma Guttman-Yassky, MD, PhD; Riya Gandhi, MA
Complete hair loss doesn't necessarily mean treatment failure in alopecia areata. Examine the latest evidence on therapeutic response, severe disease, and evolving treatment strategies.
Complete hair loss doesn't necessarily mean treatment failure in alopecia areata. Examine the latest evidence on therapeutic response, severe disease, and evolving treatment strategies.
Complete hair loss doesn't...
08/06/2026
The Dermatologist
Guttman
Videos
Myth Buster: Alopecia Areata is Just Hair Loss
08/06/2026
Emma Guttman-Yassky, MD, PhD; Riya Gandhi, MA
Alopecia areata is more than hair loss. Dr Emma Guttman discusses the disease's psychosocial burden, autoimmune nature, and why viewing AA as purely cosmetic can undermine patient care.
Alopecia areata is more than hair loss. Dr Emma Guttman discusses the disease's psychosocial burden, autoimmune nature, and why viewing AA as purely cosmetic can undermine patient care.
Alopecia areata is more than...
08/06/2026
The Dermatologist

Quizzes

severe hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa Risk Factor for Infection Following Procedures
07/26/2022
Jessica Garlewicz
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following...
07/26/2022
The Dermatologist
hidradenitis suppurativa under arm
Quiz
Trivia: Internalized Skin Bias in HS
05/17/2022
Jessica Garlewicz
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options...
05/17/2022
The Dermatologist
HS lesions
Quiz
Trivia: Are Female Patients With HS At High Risk for Adverse Pregnancy Outcomes?
12/21/2021
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: How are Patients With HS and Hepatitis B or C Systemically Treated?
12/21/2021
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: What is the Optimal Dose Regimen Recommended for HS Lesions?
12/21/2021
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of...
12/21/2021
The Dermatologist
hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa and the Risk for Hepatitis B and C
12/20/2021
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with...
12/20/2021
The Dermatologist
hidradenitis in armpit
Quiz
Trivia: Characteristics Tied to New Hidradenitis Suppurativa Diagnoses
12/17/2021
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD,...
12/17/2021
The Dermatologist
hidradenitis
Quiz
Trivia: Risk for Therapy Discontinuation Among Patients With HS
12/10/2021
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of...
12/10/2021
The Dermatologist
hidradenitis tunneling
Quiz
Trivia: Ranking of Monotherapies for Hidradenitis Suppurativa
12/03/2021
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the...
12/03/2021
The Dermatologist
Hidradenitis Suppurativa, as shown here, is a terrible condition that can affect pediatric patients and their HS treatment.
Quiz
Trivia: Physical and Psychosocial Comorbidities in Pediatric HS
09/28/2021
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these...
09/28/2021
The Dermatologist
itch
Quiz
Clinical Implications of Type 2 Inflammation in Chronic Spontaneous Urticaria
09/21/2026
Riya Gandhi, MA
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of...
09/21/2026
The Dermatologist
random molecule
Quiz
Understanding Type 2 Inflammatory Mechanisms in Chronic Spontaneous Urticaria
09/14/2026
Riya Gandhi, MA
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of...
09/14/2026
The Dermatologist
AD
Quiz
Pediatric AD Quiz: Biologic Therapy Challenges in Children
08/10/2026
Riya Gandhi, MA
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of...
08/10/2026
The Dermatologist
AD
Quiz
Pediatric AD Quiz: When to Escalate to Systemic Therapy
08/10/2026
Riya Gandhi, MA
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment...
08/10/2026
The Dermatologist
Quiz
Type 2 Endotypes and Therapeutic Strategy in Prurigo Nodularis
06/25/2026
Riya Gandhi, MA
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type...
06/25/2026
The Dermatologist
itch
Quiz
Fibrosis and Persistent Itch in Prurigo Nodularis
06/15/2026
Riya Gandhi, MA
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding...
06/15/2026
The Dermatologist
brain
Quiz
Neuroimmune Mechanisms and Cytokine Signaling in Prurigo Nodularis
06/05/2026
Riya Gandhi, MA
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in...
06/05/2026
The Dermatologist
Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist

News

Face
FDA Alerts
Bimekizumab FDA Approved for Moderate to Severe Hidradenitis Suppurativa
11/20/2024
Riya Gandhi, MA
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug...
11/20/2024
The Dermatologist
Hidradenitis Suppurativa
News
Evolving Treatment Paradigms for Hidradenitis Suppurativa: The Role of Biologics
10/31/2024
Jessica Garlewicz
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS...
10/31/2024
The Dermatologist
FDA Alerts
Secukinumab Approved as New Biologic Treatment Option for Hidradenitis Suppurativa
11/01/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug...
11/01/2023
The Dermatologist
News
Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa
07/18/2023
Jessica Garlewicz
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a...
07/18/2023
The Dermatologist
News
Smoking and Obesity Are Important Research Questions for Managing Hidradenitis Suppurativa
04/10/2023
Lisa Kuhns, PhD, MD
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority...
04/10/2023
The Dermatologist
News
Complete Remission of Hidradenitis Suppurativa Reported After Treatment With Thoracodorsal Artery Perforator Flap
04/05/2023
Lisa Kuhns, PhD, MD
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator...
04/05/2023
The Dermatologist
News
Effectiveness and Pain Reduction Identified as the Most Important Treatment Attributes in Hidradenitis Suppurativa Management
01/31/2023
Lisa Kuhns, PhD, MD
In a multinational discrete choice experiment, researchers aimed to determine which treatment attributes adult patients with HS in Europe consider the most important in treatment decision-making.
In a multinational discrete choice experiment, researchers aimed to determine which treatment attributes adult patients with HS in Europe consider the most important in treatment decision-making.
In a multinational discrete...
01/31/2023
The Dermatologist
News
Hidradenitis Suppurativa Contributes to Relationship Disturbances
12/08/2022
Lisa Kuhns, PhD, MD
Researchers aimed to determine relationship disturbances in HS using an anonymous electronic survey.
Researchers aimed to determine relationship disturbances in HS using an anonymous electronic survey.
Researchers aimed to determine...
12/08/2022
The Dermatologist
News
Pediatric Hidradenitis Suppurativa Presents Similar Clinical Spectrum to Adult-Onset Disease
11/30/2022
Lisa Kuhns, PhD, MD
Researchers performed a cross-sectional study on the clinical features and treatment approaches of pediatric HS.
Researchers performed a cross-sectional study on the clinical features and treatment approaches of pediatric HS.
Researchers performed a...
11/30/2022
The Dermatologist
News
Stigmatization Has a Debilitating Impact on Patients With Hidradenitis Suppurativa
11/18/2022
Lisa Kuhns, PhD, MD
Researchers performed an observational study that aimed to assess how feelings of stigmatization may relate to patient quality of life, depression, and social anxiety.
Researchers performed an observational study that aimed to assess how feelings of stigmatization may relate to patient quality of life, depression, and social anxiety.
Researchers performed an...
11/18/2022
The Dermatologist
News
Global Psoriasis Burden Nearly Doubled Over 3 Decades, Economic Costs Reach $149 Billion
09/03/2026
Jessica Garlewicz
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in psoriasis cases, effects on quality of life, and associated economic costs.
Investigators assessed trends in...
09/03/2026
The Dermatologist
FDA Alerts
FDA Approves Lisraya as First Oral Therapy for Adult Dermatomyositis
08/31/2026
Coleen Stern, MA
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients, this approval provides a new alternative targeting the JAK-mediated inflammation that damages the muscles and skin in dermatomyositis to control both cutaneous and systemic manifestations.
For dermatologists and patients,...
08/31/2026
The Dermatologist
FDA Alerts
FDA Grants Accelerated Approval to Tudriqev for PD-1-Refractory Advanced Melanoma
08/07/2026
Jessica Garlewicz
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma.
The US Food and Drug...
08/07/2026
The Dermatologist
roflum
FDA Alerts
FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis in Children as Young as 2 Years
06/30/2026
Riya Gandhi, MA
The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.
The expanded indication makes roflumilast cream 0.3% the first once-daily, steroid-free topical therapy approved for plaque psoriasis in children aged 2 years and older, providing a new long-term treatment option for pediatric patients.
The expanded indication makes...
06/30/2026
The Dermatologist
FDA Alert
FDA Alerts
FDA Approves Every-8-Week Maintenance Dosing Option for Lebrikizumab in Atopic Dermatitis
06/10/2026
Jessica Garlewicz
The FDA approved an every-8-week maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz), providing a new administration option for adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic...
The FDA approved an every-8-week maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz), providing a new administration option for adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic...
The FDA approved an every-8-week...
06/10/2026
The Dermatologist
psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
FDA Alerts
FDA Approves Icotyde (icotrokinra) for the Treatment of Moderate-To-Severe Plaque Psoriasis in Adults and Pediatric Patients
03/18/2026
Jessica Garlewicz
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug...
03/18/2026
The Dermatologist
FDA Alerts
FDA Approves Cosentyx for the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate-To-Severe Hidradenitis Suppurativa
03/17/2026
Jessica Garlewicz
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug...
03/17/2026
The Dermatologist
AD
News
Mixed Associations Between Socioeconomic Status and Pediatric Atopic Dermatitis Highlight Research Gaps
03/11/2026
Jessica Garlewicz
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to...
03/11/2026
The Dermatologist
FDA Alerts
FDA Approves Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis
03/10/2026
Jessica Garlewicz
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food...
03/10/2026
The Dermatologist

Popular Articles

NRS Approved Features
Myths and Updates in Rosacea Treatment
10/07/2024
Linda Stein Gold, MD
Dispelling common misconceptions about the disease and advancing the development of more tolerable topical and oral therapies can offer hope for improved patient outcomes.
Dispelling common misconceptions about the disease and advancing the development of more tolerable topical and oral therapies can offer hope for improved patient outcomes.
Dispelling common misconceptions...
10/07/2024
The Dermatologist
Illustration of a T cell
QUIZ
Test Your Knowledge: The Immunology of Alopecia Areata
11/04/2024
11/04/2024
The Dermatologist
PsA
FDA Alerts
Bimekizumab FDA Approved for the Treatment of Psoriatic Arthritis
09/24/2024
Riya Gandhi, MA
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug...
09/24/2024
The Dermatologist
Case Report
Successful Treatment of Melasma in Fitzpatrick Skin Type IV
10/07/2024
Monica Khadka, BA, BS; Kerry C. Hennessy, MD; Lilia M. Correa-Selm, MD, FAAD
Nonablative Alexandrite laser therapy may be an effective method of treating melasma in patients with darker skin types.
Nonablative Alexandrite laser therapy may be an effective method of treating melasma in patients with darker skin types.
Nonablative Alexandrite laser...
10/07/2024
The Dermatologist
psoriatic arthritis
News
Early Diagnosis May Be Crucial for Psoriatic Arthritis
09/25/2024
Jessica Garlewicz
One of the primary diagnostic challenges is recognizing early inflammatory signs in the synovium and enthesis.
One of the primary diagnostic challenges is recognizing early inflammatory signs in the synovium and enthesis.
One of the primary diagnostic...
09/25/2024
The Dermatologist
september 2026

Current Issue

September 2026
Volume 34
Issue 6
Current Issue
Issue Archive

Latest Quizzes and Trivia

severe hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa Risk Factor for Infection Following Procedures
07/26/2022
Jessica Garlewicz
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following...
07/26/2022
The Dermatologist
hidradenitis suppurativa under arm
Quiz
Trivia: Internalized Skin Bias in HS
05/17/2022
Jessica Garlewicz
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options...
05/17/2022
The Dermatologist
HS lesions
Quiz
Trivia: Are Female Patients With HS At High Risk for Adverse Pregnancy Outcomes?
12/21/2021
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: How are Patients With HS and Hepatitis B or C Systemically Treated?
12/21/2021
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: What is the Optimal Dose Regimen Recommended for HS Lesions?
12/21/2021
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of...
12/21/2021
The Dermatologist
hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa and the Risk for Hepatitis B and C
12/20/2021
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with...
12/20/2021
The Dermatologist
hidradenitis in armpit
Quiz
Trivia: Characteristics Tied to New Hidradenitis Suppurativa Diagnoses
12/17/2021
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD,...
12/17/2021
The Dermatologist
hidradenitis
Quiz
Trivia: Risk for Therapy Discontinuation Among Patients With HS
12/10/2021
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of...
12/10/2021
The Dermatologist
hidradenitis tunneling
Quiz
Trivia: Ranking of Monotherapies for Hidradenitis Suppurativa
12/03/2021
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the...
12/03/2021
The Dermatologist
Hidradenitis Suppurativa, as shown here, is a terrible condition that can affect pediatric patients and their HS treatment.
Quiz
Trivia: Physical and Psychosocial Comorbidities in Pediatric HS
09/28/2021
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these...
09/28/2021
The Dermatologist
itch
Quiz
Clinical Implications of Type 2 Inflammation in Chronic Spontaneous Urticaria
09/21/2026
Riya Gandhi, MA
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of...
09/21/2026
The Dermatologist
random molecule
Quiz
Understanding Type 2 Inflammatory Mechanisms in Chronic Spontaneous Urticaria
09/14/2026
Riya Gandhi, MA
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of...
09/14/2026
The Dermatologist
AD
Quiz
Pediatric AD Quiz: Biologic Therapy Challenges in Children
08/10/2026
Riya Gandhi, MA
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of...
08/10/2026
The Dermatologist
AD
Quiz
Pediatric AD Quiz: When to Escalate to Systemic Therapy
08/10/2026
Riya Gandhi, MA
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment...
08/10/2026
The Dermatologist
Quiz
Type 2 Endotypes and Therapeutic Strategy in Prurigo Nodularis
06/25/2026
Riya Gandhi, MA
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type...
06/25/2026
The Dermatologist
itch
Quiz
Fibrosis and Persistent Itch in Prurigo Nodularis
06/15/2026
Riya Gandhi, MA
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding...
06/15/2026
The Dermatologist
brain
Quiz
Neuroimmune Mechanisms and Cytokine Signaling in Prurigo Nodularis
06/05/2026
Riya Gandhi, MA
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in...
06/05/2026
The Dermatologist
Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use